传奇生物(LEGN)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

LEGN 传奇生物

已收盘 04-24 16:00:00 EDT

45.17

-2.28

-4.81%

盘后45.17

+0.000.00%

19:29 EDT

最高48.55	最低45.12	成交量108.91万
今开48.18	昨收47.45	日振幅7.23%
总市值82.17亿	流通市值35.86亿	总股本1.82亿
成交额5,006万	换手率1.37%	流通股本7,938万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

{"stockData":{"symbol":"LEGN","market":"US","secType":"STK","nameCN":"传奇生物","latestPrice":45.17,"timestamp":1713988800000,"preClose":47.45,"halted":0,"volume":1089075,"hourTrading":{"tag":"盘后","latestPrice":45.17,"preClose":45.17,"latestTime":"19:29 EDT","volume":4644,"amount":209781.3,"timestamp":1714001360193},"delay":0,"floatShares":79384610,"shares":181911034,"eps":-2.943241,"marketStatus":"已收盘","marketStatusCode":5,"change":-2.28,"latestTime":"04-24 16:00:00 EDT","open":48.18,"high":48.55,"low":45.12,"amount":50059403.164875,"amplitude":0.072287,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.943241,"exchange":"NASDAQ","tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1714032000000},"adr":0,"listingDate":1591329600000,"adjPreClose":47.45,"adrRate":2,"postHourTrading":{"tag":"盘后","latestPrice":45.17,"preClose":45.17,"latestTime":"19:29 EDT","volume":4644,"amount":209781.3,"timestamp":1714001360193},"volumeRatio":0.899816},"requestUrl":"/m/hq/s/LEGN","defaultTab":"news","newsList":[{"id":"2429156276","title":"欧盟委员会批准 CARVYKTI®用于复发和难治性多发性骨髓瘤患者的二线治疗","url":"https://stock-news.laohu8.com/highlight/detail?id=2429156276","media":"美通社","top":-1,"share":"https://www.laohu8.com/m/news/2429156276?lang=zh_cn&edition=full","pubTime":"2024-04-23 14:36","pubTimestamp":1713854160,"startTime":"0","endTime":"0","summary":"BCMA主要表达于恶性多发性骨髓瘤B细胞谱系、晚期B细胞和浆细胞的表面。2022年2月，西达基奥仑赛获得美国FDA批准上市，5月获得欧盟EC授予的附条件上市许可，9月获得日本MHLW批准上市，用于治疗复发或难治性多发性骨髓瘤成人患者，商品名为CARVYKTI。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4394792_ZH94792_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2429158464","title":"强生(JNJ.US)&传奇生物CAR-T疗法再获欧盟批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2429158464","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2429158464?lang=zh_cn&edition=full","pubTime":"2024-04-23 13:51","pubTimestamp":1713851483,"startTime":"0","endTime":"0","summary":"西达基奥仑赛是一种靶向B细胞成熟抗原的CAR-T疗法。2017年12月，强生旗下强生创新制药与传奇生物签订了全球独家许可和合作协议，以开发和商业化西达基奥仑赛。2022年2月，西达基奥仑赛获得美国FDA批准上市，5月获得EC授予的附条件上市许可，用于治疗复发或难治性多发性骨髓瘤成人患者，这些患者至少接受过3种前期疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042313561587a4794c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042313561587a4794c&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2429184959","title":"金斯瑞(01548.HK)：传奇生物药物获欧盟批准治疗骨髓瘤","url":"https://stock-news.laohu8.com/highlight/detail?id=2429184959","media":"阿斯达克财经","top":-1,"share":"https://www.laohu8.com/m/news/2429184959?lang=zh_cn&edition=full","pubTime":"2024-04-23 09:22","pubTimestamp":1713835320,"startTime":"0","endTime":"0","summary":"金斯瑞生物科技的非全资附属传奇生物公布，欧盟委员会已批准CARVYKTI 用于治疗复发和难治性多发性骨髓瘤成人患者，该些患者既往接受过至少一种治疗，包括蛋白酶体抑制剂和免疫调节剂，在最后一次治疗中已证明疾病进展，并且对来那度胺难治。","market":"fut","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20211125141320348_s.jpeg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20211125141320348_s.jpeg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1344142/latest-news/AAFN","is_publish_highlight":false,"gpt_icon":0},{"id":"2429189305","title":"金斯瑞生物科技(01548)：传奇生物宣布欧盟委员会批准 CARVYKTI 用于复发难治性多发性骨髓瘤患者二线治疗","url":"https://stock-news.laohu8.com/highlight/detail?id=2429189305","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2429189305?lang=zh_cn&edition=full","pubTime":"2024-04-23 08:44","pubTimestamp":1713833040,"startTime":"0","endTime":"0","summary":"智通财经APP讯，金斯瑞生物科技(01548)发布公告，该公司非全资附属公司传奇生物已于2024年4月22日(纽约时间，于2024年4月23日香港交易时段前)向美国证监会(SEC)提交 6-K 表格，欧盟委员会已批准 CARVYKTI®(ciltacabtagene autoleucel，cilta-cel)用于治疗复发性难治性多发性骨髓瘤成年患者，这些患者此前至少接受过一种治疗(包括蛋白酶体抑制剂(PI)和一种免疫调节剂(IMiD))，患者在最后一次治疗中显示出疾病进展，并且对来那度胺耐药 。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1107292.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2428375317","title":"Scotiabank：上调传奇生物(LEGN.US)评级，由与大盘持平调整至跑赢大盘评级, 目标价由65.00美元调整至65.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2428375317","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2428375317?lang=zh_cn&edition=full","pubTime":"2024-04-17 20:25","pubTimestamp":1713356728,"startTime":"0","endTime":"0","summary":"Scotiabank：上调传奇生物(LEGN.US)评级，由与大盘持平调整至跑赢大盘评级, 目标价由65.00美元调整至65.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404172025318b2f68b6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404172025318b2f68b6&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2428033598","title":"HC Wainwright & Co.：重申传奇生物(LEGN.US)评级，由买入调整至买入评级, 目标价87.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2428033598","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2428033598?lang=zh_cn&edition=full","pubTime":"2024-04-17 01:15","pubTimestamp":1713287724,"startTime":"0","endTime":"0","summary":"HC Wainwright & Co.：重申传奇生物(LEGN.US)评级，由买入调整至买入评级, 目标价87.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404170115298b2b4ed8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404170115298b2b4ed8&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2427820575","title":"传奇生物盘中异动 股价大跌5.00%","url":"https://stock-news.laohu8.com/highlight/detail?id=2427820575","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2427820575?lang=zh_cn&edition=full","pubTime":"2024-04-16 21:30","pubTimestamp":1713274223,"startTime":"0","endTime":"0","summary":"北京时间2024年04月16日21时30分，传奇生物股票出现波动，股价大幅跳水5.00%。截至发稿，该股报49.13美元/股，成交量1.6151万股，换手率0.01%，振幅1.69%。机构评级方面，在所有20家参与评级的机构中，85%的券商给予买入建议，15%的券商给予持有建议，无券商给予卖出建议。传奇生物股票所在的生物技术行业中，整体涨幅为0.00%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024041621302387e80f63&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024041621302387e80f63&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2427725822","title":"BUZZ-传奇生物技术公司因与 J&J 合作的血液癌症疗法第一季度销售额下滑而下滑","url":"https://stock-news.laohu8.com/highlight/detail?id=2427725822","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2427725822?lang=zh_cn&edition=full","pubTime":"2024-04-16 21:26","pubTimestamp":1713274004,"startTime":"0","endTime":"0","summary":"    4月16日 - ** 细胞疗法开发商传奇生物科技  股价盘前下跌约9%，至47美元 ** 强生公司  报告称， ，联想合作的癌症细胞疗法Carvykti的第一季度销售额低于预期。** Carvykti 最近获准用于病情较轻的一种血癌患者，其第一季度销售额为 1.57 亿美元。** Carvykti 是 10 种产品之一，J&J 预计其最高销售额将超过 50 亿美元 ** 截至上一交易日收盘，LEGN股价累计下跌约14","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2426654135","title":"港股异动 | 金斯瑞生物科技(01548)现涨近5% 传奇生物CARVYKTI获FDA批准二线治疗多发性骨髓瘤","url":"https://stock-news.laohu8.com/highlight/detail?id=2426654135","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2426654135?lang=zh_cn&edition=full","pubTime":"2024-04-09 13:54","pubTimestamp":1712642050,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，金斯瑞生物科技(01548)现涨近5%，截至发稿，涨4.75%，报13.22港元，成交额8406.61万港元。消息面上，传奇生物4月5日宣布，美国食药监局(FDA)已批准CARVYKTI（西达基奥仑赛）用于治疗复发或难治性多发性骨髓瘤（RRMM）患者，这些患者既往至少接受过一线治疗(包括蛋白酶体抑制剂和免疫调节剂)且对来那度胺耐药。国联证券指出，考虑到2023年CARVYKTI在MM末线（四+线）治疗即录得销售5亿美元，相信随着CARVYKTI获批二-四线治疗，以及2024年传奇生物与强生进一步扩大欧美细胞疗法产能供给，CARVYKTI有望实现加速商业化放量。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1099858.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2426564949","title":"金斯瑞(01548.HK)附属传奇生物CARVYKTI获FDA批准骨髓瘤二线治疗","url":"https://stock-news.laohu8.com/highlight/detail?id=2426564949","media":"阿斯达克财经","top":-1,"share":"https://www.laohu8.com/m/news/2426564949?lang=zh_cn&edition=full","pubTime":"2024-04-09 01:37","pubTimestamp":1712597820,"startTime":"0","endTime":"0","summary":"金斯瑞生物科技(01548.HK) 公布，附属传奇生物获美国食品药品监督管理局(FDA)批准CARVYKTI用于治疗复发或难治性多发性骨髓瘤成人患者。CARVYKTI是首个且唯一获批用于多发性骨髓瘤患者二线治疗的B细胞成熟抗原靶向疗法。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2024-04-08 16:25。)AASTOCKS新闻","market":"hk","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20190702162421146_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20190702162421146_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1340774/latest-news/AAFN","is_publish_highlight":false,"gpt_icon":0},{"id":"2425997704","title":"传奇生物CARVYKTI获批FDA二线治疗多发性骨髓瘤，市场关注度提升","url":"https://stock-news.laohu8.com/highlight/detail?id=2425997704","media":"和讯网","top":-1,"share":"https://www.laohu8.com/m/news/2425997704?lang=zh_cn&edition=full","pubTime":"2024-04-08 21:25","pubTimestamp":1712582703,"startTime":"0","endTime":"0","summary":"美国FDA批准CARVYKTI用于多发性骨髓瘤患者二线治疗金斯瑞生物科技非全资附属公司传奇生物科技股份有限公司，于2024年4月5日向美国证监会提交6-K表格。此次提交文件中，传奇生物宣布美国食品药品管理局批准CARVYKTI用于治疗复发或难治性多发性骨髓瘤成人患者。此次批准为多发性骨髓瘤患者提供了新的治疗选择。CARVYKTI作为一种创新疗法，有望改善患者的生存质量和预后。市场对CARVYKTI的关注度将持续上升，二级市场投资者可关注其商业化前景及潜在收益。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404082135378754a59b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404082135378754a59b&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2425993365","title":"金斯瑞生物科技(01548)：传奇生物宣布美国FDA批准CARVYKTI用于复发或难治性多发性骨髓瘤患者二线治疗","url":"https://stock-news.laohu8.com/highlight/detail?id=2425993365","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2425993365?lang=zh_cn&edition=full","pubTime":"2024-04-08 19:49","pubTimestamp":1712576965,"startTime":"0","endTime":"0","summary":"智通财经APP讯，金斯瑞生物科技(01548)发布公告，传奇生物科技股份有限公司(传奇生物，为公司非全资附属公司，其股份以美国存托股份形式于美国纳斯达克全球精选市场上市)已于2024年4月5日向美国证监会提交 6-K 表格，并宣布，美国食品药品管理局(美国FDA)已批准CARVYKTI®(西达基奥仑赛，cilta-cel)用于治疗复发或难治性多发骨髓瘤成人患者，这些患者既往至少接受过一线治疗(包括蛋白酶体抑制剂和免疫调节剂)且对来那度胺耐药 。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1099583.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2425610426","title":"传奇生物CAR-T在美获批二线适应症 今年销售额有望破10亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2425610426","media":"经济观察网","top":-1,"share":"https://www.laohu8.com/m/news/2425610426?lang=zh_cn&edition=full","pubTime":"2024-04-07 21:18","pubTimestamp":1712495919,"startTime":"0","endTime":"0","summary":"经济观察网 记者 瞿依贤 经济观察网 记者 瞿依贤 4月6日，传奇生物宣布其CAR-T产品——西达基奥仑赛在美国获批用于复发或难治性多发性骨髓瘤患者的二线治疗。传奇生物合作伙伴强生预测，这款药今年的销售额会突破10亿美元。西达基奥仑赛自美国上市以后的累计销售额为6.3亿美元，其中2023年的销售额超过5亿美元。强生则预计，二线适应症在美国获批后，西达基奥仑赛今年的销售收入将突破10亿美元，未来的销售峰值会超过50亿美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404072125318afab5e7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404072125318afab5e7&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2425570126","title":"全球首个获批用于多发性骨髓瘤二线治疗的CAR-T，花落中国药企","url":"https://stock-news.laohu8.com/highlight/detail?id=2425570126","media":"第一财经","top":-1,"share":"https://www.laohu8.com/m/news/2425570126?lang=zh_cn&edition=full","pubTime":"2024-04-06 18:16","pubTimestamp":1712398560,"startTime":"0","endTime":"0","summary":"如何将CAR-T细胞疗法推向前线治疗，是每家CAR-T企业试图努力的方向。由此西达基奥仑赛也成为全球首个且唯一获批多发性骨髓瘤二线治疗的CAR-T产品。西达基奥仑赛是传奇生物的主打产品，该药首度于2022年2月28日在美国获批上市，用于治疗既往接受过至少四线治疗的复发或难治性多发性骨髓瘤成人患者，这是首款走出国门的中国原创CAR-T细胞治疗药物。该药是全球范围内第7款上市的CAR-T产品，也是第2款靶向BCMA的CAR-T产品。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024040618165787e4a72e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024040618165787e4a72e&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2425550013","title":"美国 FDA 允许扩大使用百时美施贵宝的细胞疗法","url":"https://stock-news.laohu8.com/highlight/detail?id=2425550013","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2425550013?lang=zh_cn&edition=full","pubTime":"2024-04-05 21:09","pubTimestamp":1712322550,"startTime":"0","endTime":"0","summary":"((自动化翻译由路透提供，请见免责声明 ))    路透社4月5日 - 美国食品和药物管理局周五允许百时美施贵宝  和2seventybio公司  的细胞疗法Abecma用于病情较轻的一种血癌患者。 卫生监管机构还在审查强生公司  及其合作伙伴传奇生物技术公司  的另一种癌症细胞疗法Carvykti，以用于病情较轻的患者。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2424447867","title":"传奇生物的下一个出海里程碑 | 见智研究","url":"https://stock-news.laohu8.com/highlight/detail?id=2424447867","media":"华尔街见闻","top":-1,"share":"https://www.laohu8.com/m/news/2424447867?lang=zh_cn&edition=full","pubTime":"2024-04-03 15:55","pubTimestamp":1712130944,"startTime":"0","endTime":"0","summary":"4月5日，传奇生物CAR-T疗法Carvykti迎来PDUFA关键时点。","market":"hk","thumbnail":"https://wpimg-wscn.awtmt.com/1d65246e-c444-4482-9c7c-91c7c1593add.png","type":0,"news_type":0,"thumbnails":["https://wpimg-wscn.awtmt.com/1d65246e-c444-4482-9c7c-91c7c1593add.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://wallstreetcn.com/articles/3711973","is_publish_highlight":false,"gpt_icon":0},{"id":"2424913187","title":"金斯瑞生物科技(01548)：传奇生物美国公司与诺华制药公司签订主要生产和供应服务协定","url":"https://stock-news.laohu8.com/highlight/detail?id=2424913187","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2424913187?lang=zh_cn&edition=full","pubTime":"2024-04-01 18:37","pubTimestamp":1711967841,"startTime":"0","endTime":"0","summary":"合作伙伴将与诺华合作，促进诺华执行合同生产服务所需的资讯交换，并获得适用的执照和许可。该协定还包括诺华在执行合同生产服务时应满足的特定绩效指标。此外，合作伙伴将被要求给诺华报销用于生产产品的某些原材料的成本。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1097162.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2421334643","title":"中国新药杀疯了","url":"https://stock-news.laohu8.com/highlight/detail?id=2421334643","media":"虎嗅APP","top":-1,"share":"https://www.laohu8.com/m/news/2421334643?lang=zh_cn&edition=full","pubTime":"2024-03-23 16:39","pubTimestamp":1711183164,"startTime":"0","endTime":"0","summary":"出品 | 虎嗅医疗组作者 | 陈广晶编辑 | 王一鹏头图 | 视觉中国中国新药杀疯了。“11:0全票通过！”美国FDA肿瘤药物咨询委员会（ODAC）全票认可了西达基奥仑赛安全有效性评估结果，北京时间3月16日凌晨3点50分，传奇生物通过官方微信公众号第一时间分享了这一喜讯。全票通过的结果，不仅意味着，西达基奥仑赛或将很快获批用...","market":"us","thumbnail":"https://inews.gtimg.com/om_ls/OTKcWa_vZKYCrlu73giGIw2jiP9AHZZ6Fb2tvtmhq_KdoAA_294195/0","type":0,"news_type":0,"thumbnails":["https://inews.gtimg.com/om_ls/OTKcWa_vZKYCrlu73giGIw2jiP9AHZZ6Fb2tvtmhq_KdoAA_294195/0"],"rights":{"source":"tencent_tech","url":"https://new.qq.com/rain/a/20240323A05W0800","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.title{#titleStyle#}a{#lv2TextColor#}.author, .pubtime{#sourceStyle#; display: inline-block;} .pubtime{margin-left: 3px;}strong{font-weight:500;#lv2TextColor#}","selectors":".main-wrapper","filters":".follow_top, .channel-entry, .collapseWrapper, .pic, .gap, .showDividingLine, .loader, .container, .ct-sumary, .nav, .landad, .hairline-top, .footer, .recommend-modules, .headroom-wrapper, .elevator","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://new.qq.com/rain/a/20240323A05W0800","is_publish_highlight":false,"gpt_icon":0},{"id":"2420275477","title":"传奇生物盘中异动 早盘股价大跌5.13%报61.34美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2420275477","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2420275477?lang=zh_cn&edition=full","pubTime":"2024-03-19 22:49","pubTimestamp":1710859758,"startTime":"0","endTime":"0","summary":"北京时间2024年03月19日22时49分，传奇生物股票出现异动，股价大幅跳水5.13%。截至发稿，该股报61.34美元/股，成交量28.0458万股，换手率0.15%，振幅4.27%。传奇生物股票所在的生物技术行业中，整体涨幅为0.07%。其相关个股中，Fusion Pharmaceuticals Inc.、Moolec Science Sa C/Wts 、知临集团涨幅较大，Enveric Biosciences, Inc.、Hoth Therapeutics, Inc.、Clearmind Medicine Inc.较为活跃，换手率分别为814.26%、396.79%、135.83%，振幅较大的相关个股有Enveric Biosciences, Inc.、知临集团、Tracon Pharmaceuticals, Inc.，振幅分别为55.45%、49.87%、47.94%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240319224919791b7b8e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240319224919791b7b8e&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2420229690","title":"金斯瑞生物科技(01548.HK)：传奇生物发布首份ESG报告","url":"https://stock-news.laohu8.com/highlight/detail?id=2420229690","media":"格隆汇资讯","top":-1,"share":"https://www.laohu8.com/m/news/2420229690?lang=zh_cn&edition=full","pubTime":"2024-03-19 20:46","pubTimestamp":1710852416,"startTime":"0","endTime":"0","summary":"格隆汇3月19日丨金斯瑞生物科技(01548.HK)公告，传奇生物科技股份有限公司(为公司非全资附属公司)于2024年3月19日发布了其首份环境、社会和管治(ESG)报告。ESG报告概述了传奇生物的ESG计划及符合永续会计准则委员会生物技术和制药行业标准的报告、传奇生物的ESG数据收集和披露路线图，以及其ESG道路的未来成长领域。ESG报告强调了传奇生物对患者、员工和社区的承诺，标志着传奇生物于ESG道路上迈出了基础性的一步，并期待在未来几年继续推进。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024031920470287984534&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024031920470287984534&s=b","is_publish_highlight":false,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.legendbiotech.com","stockEarnings":[{"period":"1week","weight":-0.0533},{"period":"1month","weight":-0.1839},{"period":"3month","weight":-0.2105},{"period":"6month","weight":-0.2617},{"period":"1year","weight":-0.3028},{"period":"ytd","weight":-0.2114}],"compareEarnings":[{"period":"1week","weight":0.0042},{"period":"1month","weight":-0.0299},{"period":"3month","weight":0.0417},{"period":"6month","weight":0.2257},{"period":"1year","weight":0.2254},{"period":"ytd","weight":0.0638}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"传奇生物科技有限公司是一家全球性的临床级生物制药公司，致力于肿瘤和其他适应症的新药的发现和开发。该公司的差异化技术、全球开发和制造战略及专业知识使其能够针对高未满足需求的适应症生成、测试和制造下一代细胞疗法。","yearOnYearQuotes":[{"month":1,"riseRate":0.25,"avgChangeRate":-0.065278},{"month":2,"riseRate":0.5,"avgChangeRate":0.025486},{"month":3,"riseRate":0.5,"avgChangeRate":-0.027354},{"month":4,"riseRate":0.75,"avgChangeRate":0.103237},{"month":5,"riseRate":0.666667,"avgChangeRate":0.098399},{"month":6,"riseRate":1,"avgChangeRate":0.139651},{"month":7,"riseRate":0.5,"avgChangeRate":-0.042708},{"month":8,"riseRate":0,"avgChangeRate":-0.060697},{"month":9,"riseRate":0.25,"avgChangeRate":0.018606},{"month":10,"riseRate":0.5,"avgChangeRate":0.020275},{"month":11,"riseRate":0.5,"avgChangeRate":0.021203},{"month":12,"riseRate":0,"avgChangeRate":-0.047373}],"exchange":"NASDAQ","name":"传奇生物","nameEN":"Legend Biotech"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"传奇生物(LEGN)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供传奇生物(LEGN)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"传奇生物,LEGN,传奇生物股票,传奇生物股票老虎,传奇生物股票老虎国际,传奇生物行情,传奇生物股票行情,传奇生物股价,传奇生物股市,传奇生物股票价格,传奇生物股票交易,传奇生物股票购买,传奇生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"传奇生物(LEGN)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供传奇生物(LEGN)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}